(E/Z)-CCR-11 (Comp 12) is a selective CD38 inhibitor, with an IC50 of 20.8 μM against CD38 cyclase. (E/Z)-CCR-11 promotes increases in cellular NAD+ levels and interferon γ.

Novel inhibitor of PKM2-regulated signaling, suppressing non-glycolytic PKM2-regulated signaling in cancer cells

Ameltolide, a 4-aminobenzamide derivative, is an anticonvulsant agent which has been shown to be effective at inhibiting seizures in animal models.

Novel LXR inverse agonist, functioning as LXR a degrader, significantly reducing LXR protein levels in PDAC cell lines

LUF7346 is a novel hERG allosteric modulator that slows IKr deactivation and positively shifting IKr inactivation.

VUF10497 is a potent histamine H4 receptor (H4R) inverse agonist with anti-inflammatory activity.

ING-1466 is an orally active entry inhibitor of influenza A viruses (IAVs) with EC50 of 0.18 uM against IAV H1N1 (PR8-NS1-Gluc), binds to hemagglutinin (HA) and blocks HA-mediated viral infection.

Dual dopamine D2 and muscarinic M1 receptor ligand with putative antipsychotic and pro-cognitive potential

VU0366248 is a mGlu5 negative allosteric modulator.

BAY 1892005 is a small molecule that modulate mutant p53 condensation and nuclear accumulation, binds covalently to mutant p53R175H and p53Y220C and shows stabilization of p53WT and p53Y220C, exhibits anti-proliferative activity in a set of cell lines wit

Cl-amidine (hydrochloride) is a peptidylarginine deminase (PAD) inhibitor, with an IC50 5.9 μM for PAD4.

CGA-JK3 is CGA-JK3 is an ATP-competitive inhibitor of IKKβ-catalyzed kinase activity. CGA-JK3 inhibits IκBα phosphorylation in LPS (HY-D1056) - induced RAW 264.7 cells.

CCCI-01 is an inhibitor of centrosome clustering in cancer cells.

Chlorfenson is used to treat onychomycosis (nail fungus) as the primary indication.

Novel highly-selective melanocortin-4 receptor (MC4R) agonist, increasing resting energy expenditure in obese individuals

Novel potent, selective, and cell active protein arginine methyltransferase 5 (PRMT5) inhibitor

A small molecule tumor translocation inhibitor that inhibits the prostate cancer cell transcriptional program, in part by inhibition of the demethylase KDM4C (IC50=30 uM).

Novel 37/67kDa laminin receptor (LR) inhibitor, affecting both the direct 37/67kDa LR-PrP(C) interaction in vitro and the formation of the immunocomplex in live cells, inducing a progressive internalization of 37/67kDa LR and stabilization of PrP(C) on th

Novel potent inhibitor of mTOR activity, significantly suppressing macroscopic and histologic abnormalities associated with chemically-induced murine ulcerative colitis.

BRD2492 is a highly potent, selective HDAC1/2 inhibitor (IC50=2/19 nM, respectively) that displays excellent selectivity versus HDAC3 (IC50=2.08 uM, ≥110-fold selectivity) and all other HDAC isoforms, increases caspase-3 activation..

CTX-012414 is a KAT6A inhibitor with IC50 value of 0.49 μM and KD value of 0.38 -M.

Sulphenone is a chemical that can be used for the control of mite. .

Novel Inhibitor of the Mycobacterium tuberculosis Demethylmenaquinone Methyltransferase MenG

ETC-168 (ETC168) is a potent, selective MNK kinase inhibitor with biochemical IC50 of 23 and 43 nM against MNK1 and MNK2, respectively.ETC-168 acts as a MNK2-biased, dual-MNK inhibitor in cells.ETC-168 induced dose-dependent growth suppression and inhibited 50% of cell viability at 5 uM in LPS141 and MESSA, ETC-168 treatment elicited a consistent increase of cells in G0/G1 phase among LPS141, LP6, and MESSA cells in a dose-dependent manner. ETC-168 decreased cells of S and G2/M phases, while no significant induction of sub-G1 cells.Inhibition of MNK1/2 by ETC-168 elevated the expression of MNK1/2 at both transcript and protein levels in soft tissue sarcoma (STS) cells.ETC-168 effectively suppressed both p-4E and cell viability in MESSA cells, but not CGP57380 and eFT508.ETC-168 suppresseed phosphorylation of ribosomal protein S6 (RPS6) in sensitive STS cell, decreased expression of E2F1, FOXM1, and WEE1.Inhibition of MCL1 via S63845 synergizes with ETC-168 against STS cells.

PAQ (Compound 4c) is a quinoxaline derivative. PAQ is an orally active neuroprotective agent, which targets dopamine (DA) neurons and activates reticulum endoplasmic ryanodine receptor (RyR) channels, without effects on glia cells.

Highly potent, selective, competitive, and reversible inhibitor of monoamine oxidase B (MAO-B)

Org 274179-0 is a highly potent, allosteric antagonist of the thyroid-stimulating hormone receptor (TSH receptor), inhibits bTSH-, hTSH- and M22-mediated CRE-luciferase transactivation in the CHO cell line.

C902 is a small-molecule inhibitor targeting LIN28-let-7 interaction, shows dose-dependent inhibition in an EMSA validation assay with IC50 of 5 uM.

Highly potent, selective, competitive, and reversible inhibitor of monoamine oxidase B (MAO-B)

Rovazolac is a liver x receptor (LXR) modulator extracted from patent WO2013130892A1.